

Submission Details	
Status	Accepted
Open Date	02/01/2020
Deadline Date	31/01/2020
Date Submitted	29/01/2020
Type	Performance In Delivering
NHS provider	Essex Partnership University NHS Foundation Trust

Showing records 1 to 1 of 1.

Pages: 1

ID	REC Reference	IRAS	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	.Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Participants Recruited	Reason For Closure Of Trial	Please use the free text comment box for more information about the trial. Character limit: 500Comments
43169	17/SC/0595	233484	Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis	Number Agreed	3	3	Date Agreed	30/05/2020	0	09/09/2019	0	Withdrawn By Sponsor	Primary outcome of the study was positive, indicating that pimavanserin was superior to placebo in delaying time to relapse of dementia-related psychosis. As a result, the study has stopped for positive efficacy.

Showing records 1 to 1 of 1.

Pages: 1

< Back